🔎 Trials Near Me

Hjem › Lungekreft › New Mexico

Kliniske studier for Lungekreft i New Mexico

15 studier for Lungekreft søker deltakere på steder i New Mexico.

Byer i New Mexico

Offisiell studietekst (engelsk)

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

  • University of New Mexico Cancer Center, Albuquerque
  • Presbyterian Rust Medical Center/Jorgensen Cancer Center, Rio Rancho
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 2. okt. 2026 · NCT04267848

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

  • Lovelace Medical Center-Saint Joseph Square, Albuquerque
  • University of New Mexico Cancer Center, Albuquerque
  • Lovelace Women's Hospital, Albuquerque
  • og 3 flere
RekruttererObservasjonsstudieFrivillige helsepersonell ønskes velkommen
Alder 40 til 75 · Alle kjønn · Oppdatert 2. okt. 2026 · NCT05334069

Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

  • University of New Mexico Cancer Center, Albuquerque
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 1. okt. 2026 · NCT04181060

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

  • University of New Mexico Cancer Center, Albuquerque
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 1. okt. 2026 · NCT06498635

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

  • University of New Mexico Comprehensive Cancer Center, Albuquerque
  • CHRISTUS St. Vincent Regional Cancer Center, Santa Fe
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 25. sep. 2026 · NCT07222566

Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC

  • New Mexico Oncology Hematology Consultants, Ltd, Albuquerque
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 25. sep. 2026 · NCT07489066

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

  • University of New Mexico Comprehensive Cancer Center, Albuquerque
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 8. sep. 2026 · NCT06119581

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

  • University of New Mexico Cancer Center, Albuquerque
  • Memorial Medical Center-Las Cruces, Las Cruces
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 17. aug. 2026 · NCT05624996

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

  • University of New Mexico Cancer Center, Albuquerque
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 3. jun. 2026 · NCT05642572

VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

  • Presbyterian Kaseman Hospital (site 208), Albuquerque
RekruttererFase 1/2
Alder 18 til 80 · Alle kjønn · Oppdatert 11. des. 2025 · NCT03556228

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

  • Massive Bio SYNERGY-AI site, Albuquerque
RekruttererObservasjonsstudie
Alle aldre · Alle kjønn · Oppdatert 28. okt. 2025 · NCT03452774

Collection of Sputum and Labeling for Lung Cancer

  • Radiology Associates of Albuquerque, Albuquerque
RekruttererObservasjonsstudieFrivillige helsepersonell ønskes velkommen
Alder 21 og eldre · Alle kjønn · Oppdatert 1. apr. 2025 · NCT03457415

Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.